The median overall survival was 11.3 months in heavily pretreated women with metastatic disease. The study was published as a preprint and has not yet been peer reviewed.
First Look
First Look
Etoposide Plus Trastuzumab Shows Benefit in Metastatic BCa
The median overall survival was 11.3 months in heavily pretreated women with metastatic disease. The study was published as a preprint and has not yet been peer reviewed.
First Look
First Look